A Phase Ib, Single-center, Double-blind, Randomized, Placebo-controlled, Parallel-group, Multiple Ascending Dose Study to Assess Safety, Tolerability, Immunogenicity, Pharmacokinetics, and Pharmacodynamics of Subcutaneous Injections of M6495 (Anti-ADAMTS-5 Nanobody) in Participants With Symptomatic Knee Osteoarthritis
Phase of Trial: Phase I
Latest Information Update: 23 Aug 2019
Price : $35 *
At a glance
- Drugs M 6495 (Primary)
- Indications Osteoarthritis
- Focus Adverse reactions
- Sponsors Merck KGaA
- 21 Aug 2019 Status changed from active, no longer recruiting to completed.
- 05 Jul 2019 Planned End Date changed from 5 Aug 2019 to 6 Aug 2019.
- 05 Jul 2019 Status changed from recruiting to active, no longer recruiting.